TFF Pharmaceuticals Has Priced Its Underwritten Public Offering Of 19.8M At $0.25/Share, Gross Proceeds Of Approximately $4.97M
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals has priced its underwritten public offering of 19.8 million shares at $0.25 per share, with gross proceeds expected to be approximately $4.97 million.
August 15, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TFF Pharmaceuticals' public offering of 19.8 million shares at $0.25 per share could potentially dilute existing shareholders' equity.
The public offering of new shares by TFF Pharmaceuticals could dilute the value of existing shares, potentially leading to a decrease in the stock price in the short term. However, the proceeds from the offering could be used to fund growth initiatives, which could have positive long-term effects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100